Mediso Launches Next Generation MRI Spectrometer spinScan®

Mediso released their next generation MRI spectrometer spinScan® the successor to the previously used console in the nanoScan® MRI product line. The new spectrometer was optimized for MRI applications delivering an ultra-low-noise expandable RF front-end and real-time dynamic shimming.

The spectrometer is interfaced with three Mediso developed software applications to deliver a complete MRI workflow: the Sequence Development Platform for absolute control over the pulse sequences and reconstruction algorithms, the FDA approved and clinically validated InterView™ FUSION and Nucline™ for routine acquisition planning, reconstruction, image post-processing and evaluation.

Gergő Bagaméry, Director of Preclinical Product Development at Mediso commented: “Our main goal was to have a dedicated MRI spectrometer that is optimized for image quality, and works seamlessly with our clinically validated software platforms. We believe it is a big jump in performance for our research scanners as well as perfect platform for a potential clinical / OEM product line.”

The spinScan® spectrometer is based on a technology that has been continuously developed for 10+ years, featuring an FPGA SoC platform with highly scalable transceiver architecture enabling more than 128 receiver channels and microsecond gradient resolution with closed-loop control via high-speed optical interfaces. Eddy current compensation is realized through digital cross term pre-emphasis adjustment allowing for improved EPI image quality. The spinScan® spectrometer features Mediso’s extensive pulse sequence library with a wide range of readily optimized imaging protocols including all relevant anatomical sequences as well as high-end neuroimaging and spectroscopy protocols.

The console creates a future proof platform for all nanoScan® MRI systems, especially empowering the standalone MRI’s used for high-end preclinical research applications.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.